ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ivonescimab

Also written as “AK112”, “Ivonescimab Injection” and “Ivonescimab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Ovarian Neoplasms · Triple Negative Breast Neoplasms · Small Cell Lung Carcinoma, led by 5 companies.

Drug pageIvonescimab: every studyMany companies study it; this page follows only the 48 they lead. All 147 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 21, 202148 company-led studies, 39 open or runningLicense: Akeso → Summit Therapeutics, Dec 2022Next primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akesoits history only3930 open or runningphase 3since Dec 21, 2021Aug 5, 2019Dec 2026phase 2 · NCT05689853
Summit Therapeutics66 open or runningphase 3since Jun 1, 2023Jun 1, 2023Apr 2028phase 3 · NCT06767514
GlaxoSmithKlineits history only11 open or runningphase 2since May 15, 2026May 15, 2026Jun 22, 2029phase 2 · NCT07602855
Multitude Therapeuticsits history only11 open or runningphase 2since May 10, 2026May 10, 2026May 30, 2027phase 2 · NCT07590531
Shanghai Allink Biotherapeuticsits history only11 open or runningphase 2since Jul 29, 2026Jul 29, 2026Dec 31, 2027phase 2 · NCT07742956

Also a collaborator on its studies: Shanghai Virogin Biotech.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How GlaxoSmithKline, Multitude Therapeutics and Shanghai Allink Biotherapeutics relate to it is not in the registry or these sources.

History and studies of Summit Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2021Named ivonescimabINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AK112
  2. Dec 6, 2022Summit Therapeutics licensed it from AkesoLicenseThe US, Canada, Europe and Japan · announced · Summit Therapeutics (8-K exhibit)
  3. Jun 1, 2023First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05899608 · 1,600 enrolled · United States, Belgium, Canada and more
  4. Apr 25, 2024Phase 3 study in Non-Squamous Non-small Cell Lung CancerNCT06396065 · 420 enrolled · United States, Canada, France and more
  5. Jan 3, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06767514 · 780 planned · United States, Belgium, Canada and more
  6. Nov 10, 2025Phase 3 study in Colorectal NeoplasmsNCT07228832 · 900 planned · United States, Belgium, Canada and more
  7. Aug 31, 2026Phase 3 study in Carcinoma, Transitional CellNCT07815665 · 800 planned · United States
  8. Sep 29, 2026Phase 2 study in Carcinoma, Renal CellNCT07877194 · 100 planned · United States, China

Ahead

  1. Apr 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06767514
  2. May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT07228832
  3. Dec 31, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05899608
  4. Apr 12, 2029Primary completion: phase 2 study in Carcinoma, Renal CellNCT07877194

TargetBeta

PDCD1 →VEGFA →read by rule
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 6 Summit Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07877194Carcinoma, Renal Cell · United States, China2Not yet recruitingApr 12, 2029100
NCT07815665Carcinoma, Transitional Cell · United States3RecruitingOct 31, 2030800
NCT07228832Colorectal Neoplasms · United States, Belgium, Canada and more3RecruitingMay 31, 2028900
NCT06767514Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more3RecruitingApr 2028780
NCT06396065Non-Squamous Non-small Cell Lung Cancer · United States, Canada, France and more3Active, not recruitingApr 12, 2025420
NCT05899608Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more3Active, not recruitingDec 31, 20281,600

How it is read

Names in the registry

  • “AK112”, 27 entries
  • “Ivonescimab Injection”, 3 entries
  • “Ivonescimab”, 3 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “AK112 Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.